Neuroinflammation in Alzheimer's disease and prion disease

GLIA

Volumn 40, Issue 2, 2002, Pages 232-239

  Eikelenboom, P ^a,b,d   Bate, C ^c   Van Gool, W A ^b   Hoozemans, J J M ^a   Rozemuller, J M ^b   Veerhuis, R ^a   Williams, A ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Department of Psychiatry ^*  (Netherlands)

Author keywords

Acute phase proteins; Alzheimer's disease; Cytokines; Inflammation; Microglia; Prion disease

Indexed keywords

ACUTE PHASE PROTEIN; CYTOKINE;

ALZHEIMER DISEASE; ANIMAL; COMPARATIVE STUDY; DISEASE COURSE; ENCEPHALITIS; HUMAN; IMMUNOLOGY; MICROGLIA; PRION DISEASE; REVIEW;

ACUTE-PHASE PROTEINS; ALZHEIMER DISEASE; ANIMALS; CYTOKINES; DISEASE PROGRESSION; ENCEPHALITIS; HUMANS; MICROGLIA; PRION DISEASES;

EID: 0036850023     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.10146     Document Type: Review

References (68)

1. Aisen PS, Davis KL. Berg JD, et al. 2000. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54:588-593.
2. Akiyama H, Barger S, Barnum S, Bradt B, et al. 2000. Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
3. Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ. 2000. Microglia, amyloid and dementia in Alzheimer's disease. A correlative study. Neurobiol Aging 21:39-47.
4. Bales K, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P, Johnstne EM, Little SP, Cummins DJ, Ricardo P, Ghetti B, Paul SM. 1997. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nature Genet 17:263-264.
5. Bate CAW, Rutherford DS Williams A. 2000. NSAIDs inhibit PrP-induced neurotoxicity in vitro. In: Cambridge Healthtech Institute's Second Annual International Symposium: Transmissible Spongiform Encephalopathies, Alexandria, VA, USA. p 2.
6. Bate C, Reid S, Williams A. 2001. Killing of prion-damaged neurones by microglia. NeuroReport 12:2589-2594.
7. Betmouni S, Perry VH, Gordon JL.1996. Evidence for an early inflammatory response in the central nervous system of mice with scrapie. Neuroscience 74:1-5.
8. Betmouni S, Perry VH. 1999. The acute inflammatory response in CNS following injection of prion brain homogenate or normal brain homogenate. Neuropathol Appl Neurobiol 25:20-28.
9. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. 1999. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 13:63-68.
10. Brown DR, Schmidt B, Kertzschmar HA. 1996. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 380:345-347.
11. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB. 2001. In-vivo measurement of microglia in dementia. Lancet 358:461-467.
12. Eikelenboom P, Veerhuis R. 1996. The role of complement and activated microglia in pathogenesis of Alzheimer's disease. Neurobiol Aging 17:673-680.
13. Eikelenboom P, Zhan SS, van Gool WA, Allsop D. 1994. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 15 147-150.
14. Eikelenboom P, Hoogendijk WJG, Jonker C, van Tilburg W. 2002. Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer's disease. J Psychiatry Res 36:269-280.
15. Fisher O. 1910. Die presbyophrene demenz, deren anatomische grundlage und klinische abgrenzung. Z Ges Neurol Psychiatry 3:371-471.
16. Fraser H, Brown KL, Stewart K., McConnell I., McBride P, Williams A. 1996. Replication of scrapie in spleens of SCID mice follows reconstitution with wild-type bone marrow. J Gen Virol 77:1935-1940.
17. Geerlings MI, Schmand B, Braam, AW, Jonker C, Bouter LM, van Tilburg W. 2000. Depressive symptoms and risk of Alzheimer's disease in more highly educated older people. J Am Geriatr Soc 48:1092-1097.
18. Gentleman SM, Graham DI, Roberts GW. 1993. Molecular pathology of head trauma: Altered beta APP and the aetiology of Alzheimer's disease. Prog Brain Res 96:237-246.
19. Giese A, Brown DR, Groschup MH, Feldmann C, Haist I, Kretzschmar HA. 1998. Role of microglia in neuronal cell death in prion disease. Brain Pathol 8:449-457.
20. Goldgaber D, Harris HW, Hla T, Maciag T, Donelly RJ, Jacobsen JS, Vitek MP, Gajdusek DC. 1989. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A 86:7606-7610.
21. Guilian D. 1999. Microglia and the immune pathology of Alzheimer's disease. Am J Hum Genet 65:13-18.
22. Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B, Zinkernagel RM, Kalinke U, Aguzzi A. 2001. Prevention of scrapie pathogenesis by transgenic expression of anti-prion antibodies. Science 294:178-182.
23. Hoozemans JJM, Rozemuller AJM, Janssen I, De Groot CJA, Veerhuis R, Eikelenboom P. 2001a. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brains. Acta Neuropathol (Berl) 101:2-8.
24. Hoozemans JJM, Rozemuller AJM, Veerhuis R, Eikelenboom P. 2001b. Immunological aspects of Alzheimer's disease: Therapeutical implications. BioDrugs 15:325-337.
25. in t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MMB, Stricker BH. 2001. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515-1521.
26. Ishii T, Haga S, Yagashita S, Tateishi J. 1984. The presence of complements in amyloid plaques of Creutzfeldt-Jakob disease and Gerstman-Straussler-Scheinkel disease. Appl Pathol 2:370-379.
27. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, Ingham C, Sayers AR, Brown DA, Fraser JR. 2000. Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus. Neuropathol Appl Neurobiol 26:41-54.
28. Kamboh MI, Sanghera DK, Ferell RE, DeKosky ST. 1995. ApoE4-associated Alzheimer's disease risk is modified by α1-antichymotrypsin polymorphism. Nature Genet 10:468-488.
29. Landreth GE, Heneka MT. 2001. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22:937-944.
30. Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB, Hsiao-Ashe K, Frautschy SA, Cole GM. 2001. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22:983-991.
31. Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GMJ, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J. 2001. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35:72-79.
32. Ma J, Yee A, Brewer HB, Das S, Potter H. 1994, Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β protein into filaments. Nature 372:92-94.
33. Mabbott, MA, Williams A., Farquhar CF, Pasparakis M, Kollias G, Bruce ME. 2000. Tumor necrosis factor alpha-deficient, but not interleukin-6-deficient, mice resist peripheral infection with scrapie. J Virol 74:3338-3344.
34. Manuelidis L, Fritch W. Zaitsev I. 1998. Dapsone to delay symptoms in Creutzfeld-Jakob disease. Lancet 352:456.
35. McBride PA, Wilson MI, Eikelenboom P, Tunstal A, Bruce ME. 1998. Heparan sulphate proteoglycan is associated with amyloid plaques and neuroanatomically targeted PrP pathology throughout the incubation period of scrapie-infected mice. Exp Neurol 149:447-454.
36. McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, Patterson CC, McIlroy SP, Passmore AP. 2001. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia. Lancet 357:436-439.
37. McGeer PL, Schultzer M, McGeer EG. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiological studies. Neurology 47:425-432.
38. McGeer PL, McGeer EG. 2001. Inflammation, autotoxicity and Alzheimer's disease. Neurobiol Aging 22:799-809.
39. Meda L, Cassatella MA, Szenddrei GI, Otvos LJ, Baron P, Villalba M, Ferrari D, Rossi F. 1995. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 374:647-650.
40. Metchnikoff E. 1892. Lemons sur la Pathologic Comparée de l' Inflammation. Masson, Paris.
41. Nicoll JAR, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WST. 2000. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 47:365-368.
42. Nilsson LNG, Bales KR, DiCarlo G, Gordon MN, Paul SM, Potter H. 2001. α-1 Antichymotrypsin promotes β-sheet amyloid plaque formation in a transgenic mouse model of Alzheimer's disease. J Neurosci 21:1444-1451.
43. Oka A, Takashima S. 1997. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome an dementia of Alzheimer type: Specific localisation in affected neurons and axons. NeuroReport 8:161-164.
44. Outram GW, Dickinson AG, Fraser H. 1974. Reduced susceptibility to scrapie in mice after steroid administration. Nature 249:855-856.
45. Papassotiropoulos A, Bagli M, Jessen F, Bayer TA, Mayer W, Rao ML, Heun R. 1999. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk of sporadic Alzheimer's disease. Ann Neurol 45:666-668.
46. Peyrin J.-M, Lasmézas CI, Haïk S, Tagliavini F, Salmona M, Williams A, Ritchie E., Deslys J-P, Dormont D. 1999. Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. NeuroReport 10:723-729.
47. Potter H, Wefes IM, Nilsson LNG. 2001. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging 22:923-930.
48. Roberts GW, Gentleman SM, Lynch A, Graham DI. 1991. Beta A4 amyloid protein deposition in brain after head trauma. Lancet 338:1422-1423.
49. Rogers J, Cooper NR, Webster S, Schulz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Lieberburg I. 1992. Complement activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci U S A 89:10016-10020.
50. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, Nilsson LN. 1999. Translation of the alzheimer amyloid precursor protein mRNA is upregulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem 274:6421-6431.
51. Rozemuller JM, van Muiswinkel FL. 2000. Microglia and neurodegeneration. Eur J Clin Invest 30:469-470.
52. Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. 1989. Microglial cells around plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett 101:288-292.
53. Sasaki A, Hirato J, Nakazato Y. 1993. Immunohistochemical study of microglia in the Creutzfeldt-Jacob diseased brains. Acta Neuropathol 86:337-344.
54. Sainetti SM, Ingrim DM, Talwalker S, Geis GS. 2000. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. In: Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. p 180.
55. Schenk D, Barbour R, Dunn W, et al. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
56. Shen Y, Li R, McGeer EG, McGeer PL.1997. Neural expression of mRNAs for complement proteins of the classical pathways in Alzheimer brain. Brain Res 769:391-395.
57. Van Duijn CM, Hofman A. 1991. Risk factors for Alzheimer's disease. The EURODEM collaborative re-analysis of case-control studies. Neuroepidemiology 11(S1):106-113.
58. Van Gool WA, Weinsteir HC, Scheltens PK, Walstra GJ. 2001. Effect of hydrochloroquine on progression of dementia in early Alzheimer's disease: An 18-month randomised, double-blind, placebo-controlled study. Lancet 358:455-460.
59. Van Muiswinkel FL, Veerhuis R, Eikelenboom P. 1996. Amyloid (Aβ) primes cultured rat microglial cells for an enhanced phorbol myristate-acetate induced respiratory burst activity. J Neurochem 66:2468-2476.
60. Veerhuis R, Hoozemans JJM. Janssen I, Boshuizen RS, Langeveld JPM, Eikelenboom P. 2002. Adult human microglia secrete cytokines when exposed to neurotoxic prion peptide: No intermediary role for prostaglandin E2. Brain Res 925:195-203.
61. Veerhuis R, Van Breemen MJ, Hoozemans JJM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P. Amyloid β plaque-associated proteins C1q and SAP enhance the Aβ1-42 peptide induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol (in press).
62. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Butler T. Kang DE, Marquez-Sterling N, Golde TE, Koo EH. 2001. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212-216.
63. Williams AE, Lawson LJ, Perry VH, Fraser H. 1994a. Characterisation of the microglial response in scrapie. Neuropathol Appl Neurobiol 20:47-55.
64. Williams AE, van Dam, A-M, Man-A-Hing, WKH, Berkenbosch F, Eikelenboom, P Fraser H. 1994b. Cytokines, prostaglandins and lipocortin-1 are present in the brains of scrapie-infected mice. Brain Res 654:200-206.
65. Williams AE, Ryder S Blakemore WF. 1995. Monocyte recruitment into the scrapie-affected brain. Acta Neuropathol (Berl) 90:164-169.
66. 2 and lipocortin-1 in the CNS during the incubation period of murine scrapie correlates with progressive PrP accumulations. Brain Res 754:171-180.
67. Williams AE, Lucassen PJ, Ritchie D, Bruce M. 1997b. PrP deposition, microglial activation and neuronal apoptosis in murine scrapie. Exp Neurol 144:433-438.
68. Zeidler M, Johnstone EC, Bamber RWK, et al. 1997. New variant Creutzfeldt-Jakob disease: Psychiatric features. Lancet 350:908-910.